| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/09/2004 | CN1503633A Ingestible compositions contaiing odoriferous oil |
| 06/09/2004 | CN1503632A Nutritional composition for immune condition |
| 06/09/2004 | CN1502631A Carcino-embryonic untigen specific combined peptide and fusion protein with TNF-alpha |
| 06/09/2004 | CN1502628A Polyglycol modification article for acidic fibroblast growth factor and its mutant |
| 06/09/2004 | CN1502625A Oligopeptide suppressor of matrix metalloprotease 2 |
| 06/09/2004 | CN1502373A Pressure-sensitive adhesive sheet for medical use and process for producing the same |
| 06/09/2004 | CN1502369A Bioadhesive pharmaceutical compositions based on non-steroidal anti-inflammatory drugs |
| 06/09/2004 | CN1502331A Anti-angiogenic compositions and methods of use |
| 06/09/2004 | CN1502326A Rectal suppository |
| 06/09/2004 | CN1152718C Stable oxaliplatin solution preparation and preparation process thereof |
| 06/09/2004 | CN1152717C Oral medicinal preparation |
| 06/09/2004 | CN1152713C Dried blood factor composition comprising trehalose |
| 06/09/2004 | CN1152712C Freeze-dried composition of bone morphogenetic protein human MP52 |
| 06/09/2004 | CN1152689C Activated vitamin D3 emulsion-type lotions |
| 06/09/2004 | CN1152686C Stable drug composition |
| 06/09/2004 | CN1152680C Pharmaceutical composition containing liphase inhibitors and chitosan |
| 06/09/2004 | CN1152674C Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid |
| 06/09/2004 | CN1152670C Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| 06/09/2004 | CN1152669C Medicinal aerosol preparation, its preparing method and release device |
| 06/08/2004 | US6747151 Azo compounds for type I phototherapy |
| 06/08/2004 | US6747134 Antibody immunologically reactive with serine protease EOS |
| 06/08/2004 | US6747064 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 06/08/2004 | US6747055 Water-soluble drugs and methods for their production |
| 06/08/2004 | US6747014 For therapy of inflammatory bowel disorder |
| 06/08/2004 | US6746689 Intradermal-penetration agents for topical local anesthetic administration |
| 06/08/2004 | US6746688 Alkyl-ester of levodopa in solvent |
| 06/08/2004 | US6746683 Nontoxic pesticide, and method of using the same |
| 06/08/2004 | US6746677 For preventing and controlling helminthiasis, infection by acarids and arthropod endo-and ectoparasites and bacterial and viral disease in warm-blooded animals |
| 06/08/2004 | US6746661 Biocompatible component, therapeutically active component comprising a non-radioactive drug, and a radiopaque marker; seed has a size and shape suitable for passing through the bore of a 10 gauge needle |
| 06/08/2004 | US6746529 Moisture and oxygen resistance; high molecular weight film former with mono, di and trisaccharides and maltodextrin |
| 06/08/2004 | CA2100256C A method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion,and the use of said agents for said purpose |
| 06/03/2004 | WO2004046730A2 Uses of ble proteins and antibiotics from the bleomycin family |
| 06/03/2004 | WO2004046365A2 Interferon-alpha polypeptides and conjugates |
| 06/03/2004 | WO2004046328A2 Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them |
| 06/03/2004 | WO2004046309A2 Methods for inhibiting viral replication in vivo |
| 06/03/2004 | WO2004046222A1 Modified biological substance, process for producing the same, and intermediate |
| 06/03/2004 | WO2004046202A2 Bio-degradable colloid particles, in particular for pulmonary applications |
| 06/03/2004 | WO2004046200A1 Sustained release drug carrier |
| 06/03/2004 | WO2004046169A2 Activation of peptide prodrugs by hk2 |
| 06/03/2004 | WO2004045718A2 Treatment of cognitive dysfunctions' |
| 06/03/2004 | WO2004045648A1 Positional isomers of peg ifn alpha 2a |
| 06/03/2004 | WO2004045647A1 Amplification of biotin-mediated targeting |
| 06/03/2004 | WO2004045646A1 Pharmaceutical compositions having a modified vehicle |
| 06/03/2004 | WO2004045645A2 A bacteriophage preparation of enhanced stability by application of a block copolymer of ethylene oxide and propylene oxide |
| 06/03/2004 | WO2004045642A1 Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
| 06/03/2004 | WO2004045641A2 Antigen-complexes |
| 06/03/2004 | WO2004045633A2 Pharmaceutical composition comprising octreotide microparticles |
| 06/03/2004 | WO2004045594A1 Agent for dissolving dental calculi and dental caries |
| 06/03/2004 | WO2004045583A1 Liposome |
| 06/03/2004 | WO2004045581A1 Veterinary antiparasite suspension injection |
| 06/03/2004 | WO2004045571A1 Use of polymers, which contain basic amine groups, in cosmetic, dermatological or pharmaceutical formulations |
| 06/03/2004 | WO2004045549A2 Medical devices employing novel polymers |
| 06/03/2004 | WO2004045542A2 Therapeutic bioconjugates |
| 06/03/2004 | WO2004045540A2 Method for continuous, automated blending of solutions from acids and bases |
| 06/03/2004 | WO2004045537A2 Edible film for relief of cough or symptoms associated with pharyngitis |
| 06/03/2004 | WO2004045536A2 Method and compositions for temporarily incapaciting subjets |
| 06/03/2004 | WO2004045533A2 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 06/03/2004 | WO2004045506A2 Conjugated fatty acid based emulsion and methods for preparing and using same |
| 06/03/2004 | WO2004045497A2 Cd26-based therapies for cancers and immune disease |
| 06/03/2004 | WO2004045494A2 Biological glue based on thrombin-conjugated nanoparticles |
| 06/03/2004 | WO2004045491A2 Targeted double stranded rna mediated cell killing |
| 06/03/2004 | WO2004032970A3 Carriers attached to blood cells |
| 06/03/2004 | WO2004029095A3 Cohesive coprecipitates of sulfated polysaccharide and fibrillar protein and use thereof |
| 06/03/2004 | WO2004018519A3 Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
| 06/03/2004 | WO2003099228A3 Compositions and processes for inhibiting gene expression using polynucleotides |
| 06/03/2004 | WO2003088761A3 Physiologically compatible, phospholipid-containing, stable and hard matrix |
| 06/03/2004 | WO2003000928A3 Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof |
| 06/03/2004 | WO2002093998A3 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 06/03/2004 | US20040107453 Multipotent adult stem cells, sources thereof, methods of obtaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 06/03/2004 | US20040106896 System and method for forming a non-ablative cardiac conduction block |
| 06/03/2004 | US20040106825 e.g., disodium N-(5-chlorosalicyloyl)-8-amN-(10-[2-hydroxybenzoyl]amino)decanoate and disodium N-(10-[2-hydroxybenzoyl]amino)decanoate |
| 06/03/2004 | US20040106763 Linear block polymer |
| 06/03/2004 | US20040106747 Polyalkylene glycol acid additives |
| 06/03/2004 | US20040106730 Polymer complexes of glucuronoglucanes |
| 06/03/2004 | US20040106674 to provide improved formulations of a full complement of Vitamin E isomers including tocotrienols, which produce a significantly synergistic antioxidant capacity of the formulations that is greater than in heretofore known formulations or delivery |
| 06/03/2004 | US20040106636 said analgesic contains an opioid moiety of chemically modified morphine that binds to and activates an mu opioid receptor (MOR), and a tachykinin peptide substance P (SP) peptide fragment moiety that binds to and activates an SPR |
| 06/03/2004 | US20040106629 Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction |
| 06/03/2004 | US20040106617 Chemical stability of levosimendan solutions can be significantly improved if the pH of the solution is lowered from neutral to lower than 5, preferably to 4.5 or lower, most preferably to 3-4.2 |
| 06/03/2004 | US20040106590 Methods and reagents for treating infections of clostridium difficile and diseases associated therewith |
| 06/03/2004 | US20040106576 Derivatives of venlafaxine and methods of preparing and using the same |
| 06/03/2004 | US20040106568 Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation |
| 06/03/2004 | US20040106567 inhibiting expression of a gene in an extravascular mammalian cell by: a) injecting a naked polynucleotide into a blood vessel lumen; b) increasing permeability in the vessel; and, c) delivering the polynucleotide to an extravascular cell |
| 06/03/2004 | US20040106548 amide cyclization; for altering stability and specificity of receptor-targeted agents |
| 06/03/2004 | US20040106547 glucose lowering protein (GLP-1); exendins; for regulation of excess levels of blood glucose and/or regulation of gastric emptying; for treatment of diabetes and eating disorders |
| 06/03/2004 | US20040106546 comprises cyclosporin, hyaluronic acid, and polysorbate compound |
| 06/03/2004 | US20040106544 Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements |
| 06/03/2004 | US20040106542 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 06/03/2004 | US20040106154 In vivo screen using chemical inducers of dimerization |
| 06/03/2004 | US20040105980 exhibiting one or more properties, such as magnetic, thermal, optical, electrical, biological, chemical, lubrication, and rheological; core particles of specified average particle size with a plurality of coatings |
| 06/03/2004 | US20040105908 is excellent in safety and mineral absorption enhancing effects and is capable of alleviating mineral deficiency |
| 06/03/2004 | US20040105900 Extracts derived from Pueraria mirifica, Butea superba and/or Mucuna collettii and extraction thereof |
| 06/03/2004 | US20040105898 Acidified nitrite as an antimicrobial agent |
| 06/03/2004 | US20040105895 Monovalent-selective cation exchangers as oral sorbent therapy |
| 06/03/2004 | US20040105888 Buoyant polymer particles for delivery of therapeutic agents to the central nervous system |
| 06/03/2004 | US20040105887 Controlled release oxycodone compositions |
| 06/03/2004 | US20040105881 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 06/03/2004 | US20040105878 Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
| 06/03/2004 | US20040105874 comprising silicone matrix, a hydrophilic carrier, and at least one active agent comprising proteins, particularly enzymes such as hydrolases and glucose oxidase for enzymatic debridement, clotting formation and clot removal and wound healing |
| 06/03/2004 | US20040105852 Parenteral composition for treating bacterial illnesses |
| 06/03/2004 | US20040105851 Treatment of tumors with superoxide dismutase for prevention by applying to tumors |